Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05668936
Other study ID # D5671C00010
Secondary ID 2022-002479-12
Status Terminated
Phase Phase 1
First received
Last updated
Start date January 3, 2023
Est. completion date March 10, 2023

Study information

Verified date March 2023
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.


Description:

This study will be a randomized, double-blind, placebo-controlled 3-arm parallel study with a nested crossover design for positive control with moxifloxacin administration in healthy male and female participants. Participants will be randomized to receive treatment with either cotadutide during the 13-week treatment period (Arm 1) or cotadutide-placebo (Arm 2). The cotadutide-placebo treatment arm will be further divided into 2 subgroups (Arms 2A and 2B), in a nested crossover design for only the placebo-treated participants. Participants will be randomized in a 2:1:1 ratio to Arm 1, Arm 2A, and Arm 2B. Approximately 80 participants will be randomized to have 64 evaluable participants in the study. Each participant will be involved in the study for approximately 22 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 31
Est. completion date March 10, 2023
Est. primary completion date March 10, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy male and female participants of age 18 to 55 years. - Females must have a negative pregnancy test. - Have a Body Mass Index (BMI) of = 18 and = 29.9 kg/m^2. Exclusion Criteria: - History or presence of any clinically significant disease or disorder. - History or presence of gastrointestinal, hepatic or renal disease, or any other condition (including gastrointestinal surgery) known to interfere with absorption, distribution, metabolism, or excretion of drugs. - History of acute or chronic pancreatitis. - Family history of sudden cardiac death before the age of 50 of a first-degree relative. - History of additional risk factors for Torsade de Pointes (eg, heart failure, clinically important bradycardia and electrolyte disturbances eg, hypokalemia, hypocalcemia, hypomagnesemia or family history of long QT syndrome). - History of neoplastic disease - Any clinically significant abnormalities in clinical chemistry, hematology, urinalysis results or vital signs. - Any clinically significant abnormalities in rhythm, conduction, or morphology of the 12-lead resting electrocardiogram (ECG). - Any positive result on screening for serum hepatitis B surface antigen OR anti-HBc antibody, indicative of active hepatitis B (ie, participants with positive anti-HBc antibody result are acceptable if anti HBc IgM antibodies are negative), hepatitis C antibody, and Human immunodeficiency virus (HIV) antibody. - Current smokers or those who have smoked or used nicotine products (including e-cigarettes). - Known or suspected history of alcohol or drug abuse or excessive intake of alcohol. - Use of drugs with enzyme-inducing properties such as St John's Wort. - Participant has a positive test result for SARS-CoV-2 RT-PCR during screening period or at baseline. - Participant has clinical signs and symptoms consistent with COVID-19 or a history of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cotadutide
Participants will receive a subcutaneous injection of cotadutide.
Cotadutide-placebo
Participants will receive a subcutaneous injection of cotadutide-placebo.
Moxifloxacin
Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
Moxifloxacin-placebo
Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.

Locations

Country Name City State
Germany Research Site Berlin

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time-matched change-from-baseline Fridericia's correction of QT interval (QTcF) Time-matched change-from-baseline QTcF after cotadutide administration compared with placebo will be assesed using a C-QTc interval analysis. The method that removes the HR dependence of the QT interval most efficiently will be chosen as the primary correction method and its corresponding change from baseline QTc will be the primary endpoint. Up to Day 92
Secondary Change from baseline in QTcF Change from baseline in QTcF after moxifloxacin administration compared with placebo will be assessed. Up to Day 94
Secondary Change from baseline in Heart rate (HR) The effect of cotadutide on HR will be assessed. From Day 2 up to Day 92 or early discontinuation
Secondary Change from baseline in PR interval The effect of cotadutide on PR interval will be assessed. From Day 2 up to Day 92 or early discontinuation
Secondary Change from baseline in QRS interval The effect of cotadutide on QRS will be assessed. From Day 2 up to Day 92 or early discontinuation
Secondary Number of participants with significant change in QTcF The presence of categorical outliers for QTc after cotadutide administration will be assessed. From Day 2 up to Day 92 or early discontinuation
Secondary Number of participants with significant change in HR The presence of categorical outliers for HR after cotadutide administration will be assessed. From Day 2 up to Day 92 or early discontinuation
Secondary Number of participants with significant change in PR interval The presence of categorical outliers for PR after cotadutide administration will be assessed. From Day 2 up to Day 92 or early discontinuation
Secondary Number of participants with significant change in QRS interval The presence of categorical outliers for QRS after cotadutide administration will be assessed. From Day 2 up to Day 92 or early discontinuation
Secondary Number of treatment-emergent changes in T-wave morphology Morphological changes in the T-U complex after cotadutide administration will be investigated. From Day 2 up to Day 92 or early discontinuation
Secondary Number of treatment-emergent changes in U-waves presence Morphological changes in the T-U complex after cotadutide administration will be investigated. From Day 2 up to Day 92 or early discontinuation
Secondary Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast) of cotadutide AUClast as a variable of the pharmacokinetics (PK) of cotadutide will be assessed. Day 57 and Day 91
Secondary Area under concentration-time curve in the dose interval (AUCtau) of cotadutide AUCtau as a variable of the PK of cotadutide will be assessed. Day 57 and Day 91
Secondary Maximum observed plasma concentration (Cmax) of cotadutide Cmax as a variable of the PK of cotadutide will be assessed. Day 57 and Day 91
Secondary Time to reach maximum observed plasma concentration (tmax) of cotadutide tmax as a variable of the PK of cotadutide will be assessed. Day 57 and Day 91
Secondary Change from baseline in mean systolic blood pressure (SBP) The effect of cotadutide on blood pressure (BP) by Ambulatory blood pressure monitoring (ABPM) will be investigated. Up to Day 92
Secondary Change from baseline in mean diastolic blood pressure (DBP) The effect of cotadutide on BP by ABPM will be investigated. Up to Day 92
Secondary Change from baseline in mean HR The effect of cotadutide on HR by ABPM will be investigated. Up to Day 92
Secondary Placebo-corrected mean change from baseline in SBP The effect of cotadutide on BP by ABPM will be investigated. Up to Day 92
Secondary Placebo-corrected mean change from baseline in DBP The effect of cotadutide on BP by ABPM will be investigated. Up to Day 92
Secondary Placebo-corrected mean change from baseline in HR The effect of cotadutide on HR by ABPM will be investigated. Up to Day 92
Secondary Number of participants with significant change in SBP The effect of cotadutide on BP by ABPM will be investigated. Up to Day 92
Secondary Number of participants with change in DBP The effect of cotadutide on BP by ABPM will be investigated. Up to Day 92
Secondary Number of participants with significant change in HR The effect of cotadutide on HR by ABPM will be investigated. Up to Day 92
Secondary Number of participants with Adverse Events (AEs) The safety and tolerability of cotadutide will be assessed. Up to follow-up visit 28 days post last dose (approximately Day 120)
Secondary Number of participants with Antidrug Antibodies to cotadutide The immunogenicity of cotadutide will be evaluated. Day 2, 30, 57, 91 and Day 120 (follow-up visit 28 days post last dose)
See also
  Status Clinical Trial Phase
Recruiting NCT05945537 - A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH Phase 1
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Recruiting NCT05065593 - The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis N/A
Terminated NCT04171765 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Active, not recruiting NCT02912260 - Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT06054815 - Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH Phase 2
Completed NCT02784444 - A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Phase 2
Not yet recruiting NCT06160271 - Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis Phase 2
Active, not recruiting NCT05573204 - Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis Phase 2
Completed NCT04042142 - Glucagon Resistance in Patients With NAFLD N/A
Completed NCT04657523 - Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study N/A
Completed NCT04142424 - A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects Phase 1
Terminated NCT02787304 - Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04666402 - Integrated Diagnostics for Early Diagnosis of Liver Disease
Completed NCT02528305 - The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis N/A
Recruiting NCT01056133 - Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH) Phase 2
Completed NCT04806750 - Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension Phase 2
Completed NCT02960204 - Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Phase 2
Recruiting NCT05751720 - Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue Phase 1/Phase 2